Literature DB >> 29062584

Adrenal Insufficiency in Pediatric Eosinophilic Esophagitis Patients Treated with Swallowed Topical Steroids.

Stephanie Hsu1, Colleen Wood1, Zhaoxing Pan2,3, Haseeb Rahat1, Philip Zeitler1, David Fleischer3,4, Calies Menard-Katcher3,5, Glenn T Furuta3,5, Dan Atkins3,4.   

Abstract

Swallowed topical steroids (STS) are the only effective pharmacological therapy for eosinophilic esophagitis (EoE). Thus far, studies of small populations of EoE patients have reported conflicting results in relation to adrenal insufficiency (AI). We sought to measure AI in a clinical setting in children taking STS for EoE. We performed a quality improvement study of pediatric EoE patients seen in a multidisciplinary clinic, who were treated with STS for at least 3 months. Two hundred twenty-five patients completed questionnaires to assess for signs of AI. All patients were requested to have fasting morning cortisol levels completed and if abnormal (<5 μg/dL or 139 nmol/L) twice, endocrinology consultation, and low-dose adrenocorticotropic hormone stimulation test were performed. A peak stimulated cortisol level of <18 μg/dL or 500 nmol/L was diagnostic of AI. Five of 106 STS-treated EoE patients who had morning cortisol levels drawn had AI. All 5 of these patients had asthma and were on additional topical steroid treatments. The number of steroid modalities and dose of steroid were not significant risk factors. Despite this low percentage, the life-threatening potential of AI warrants patient screening, as patients with iatrogenic AI are typically asymptomatic until an emergency triggers adrenal crisis. Further multicenter studies are needed to better define the risk attributable to STS alone, particularly in patients receiving combined steroid modalities.

Entities:  

Keywords:  asthma; cortisol; eosinophilic esophagitis; esophagitis; safety

Year:  2017        PMID: 29062584      PMCID: PMC5649406          DOI: 10.1089/ped.2017.0779

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol Pulmonol        ISSN: 2151-321X            Impact factor:   1.349


  23 in total

1.  Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.

Authors:  Ranjan Dohil; Robert Newbury; Lyman Fox; John Bastian; Seema Aceves
Journal:  Gastroenterology       Date:  2010-05-07       Impact factor: 22.682

Review 2.  Diagnosis and management of eosinophilic esophagitis.

Authors:  Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2012-06-19       Impact factor: 11.382

3.  Swallowed glucocorticoid therapy for eosinophilic esophagitis in children does not suppress adrenal function.

Authors:  Katherine Q Philla; Steve B Min; Jody N Hefner; Robin S Howard; Brian J Reinhardt; Luz G Nazareno; Karen S Vogt
Journal:  J Pediatr Endocrinol Metab       Date:  2015-09       Impact factor: 1.634

4.  Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis.

Authors:  Sandeep K Gupta; Joanne M Vitanza; Margaret H Collins
Journal:  Clin Gastroenterol Hepatol       Date:  2014-06-04       Impact factor: 11.382

5.  Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.

Authors:  Evan S Dellon; David A Katzka; Margaret H Collins; Mohamed Hamdani; Sandeep K Gupta; Ikuo Hirano
Journal:  Gastroenterology       Date:  2016-11-23       Impact factor: 22.682

6.  Eosinophilic esophagitis in children and adolescents: epidemiology, clinical presentation and seasonal variation.

Authors:  Serge Alexander Sorser; Mohammed Barawi; Karen Hagglund; Mohammad Almojaned; Hernando Lyons
Journal:  J Gastroenterol       Date:  2012-05-23       Impact factor: 7.527

Review 7.  Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors:  Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2011-04-07       Impact factor: 10.793

Review 8.  Incidence and prevalence of eosinophilic esophagitis in children.

Authors:  Ing S Soon; J Decker Butzner; Gilaad G Kaplan; Jennifer C C deBruyn
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-07       Impact factor: 2.839

9.  Adrenal Suppression in Children Treated With Oral Viscous Budesonide for Eosinophilic Esophagitis.

Authors:  Shira Harel; Brenden E Hursh; Edmond S Chan; Vishal Avinashi; Constadina Panagiotopoulos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-08       Impact factor: 2.839

10.  Adrenal suppression in children treated with swallowed fluticasone and oral viscous budesonide for eosinophilic esophagitis.

Authors:  Alexandra Ahmet; Eric I Benchimol; Ellen B Goldbloom; Janice L Barkey
Journal:  Allergy Asthma Clin Immunol       Date:  2016-10-10       Impact factor: 3.406

View more
  11 in total

1.  Low detection of adrenal suppression secondary to swallowed steroids for eosinophilic esophagitis in a quality improvement project.

Authors:  Suzanne R Kochis; David W Cooke; Jennifer Dantzer; Robert Wood; Corinne Keet
Journal:  J Allergy Clin Immunol Pract       Date:  2020-07-12

Review 2.  Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine.

Authors:  Ian F Slack; Justin T Schwartz; Vincent A Mukkada; Shawna Hottinger; J Pablo Abonia
Journal:  Curr Allergy Asthma Rep       Date:  2020-06-06       Impact factor: 4.806

3.  Systematic review: adrenal insufficiency secondary to swallowed topical corticosteroids in eosinophilic oesophagitis.

Authors:  H Philpott; M K Dougherty; C C Reed; M Caldwell; D Kirk; D J Torpy; E S Dellon
Journal:  Aliment Pharmacol Ther       Date:  2018-03-05       Impact factor: 8.171

Review 4.  Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach.

Authors:  Mery Munoz-Persy; Alfredo J Lucendo
Journal:  Eur J Pediatr       Date:  2018-03-17       Impact factor: 3.183

Review 5.  New Developments in the Diagnosis and Treatment of Eosinophilic Esophagitis.

Authors:  Quan M Nhu; Fouad J Moawad
Journal:  Curr Treat Options Gastroenterol       Date:  2019-03

Review 6.  Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.

Authors:  Florence Roufosse
Journal:  Front Med (Lausanne)       Date:  2018-04-06

7.  A 12-Week Maintenance Therapy with a New Prepared Viscous Budesonide in Pediatric Eosinophilic Esophagitis.

Authors:  Salvatore Oliva; Danilo Rossetti; Paola Papoff; Antonio Tiberti; Saverio Mallardo; Danila Volpe; Cosimo Ruggiero; Giusy Russo; Debora Vezzoli; Sara Isoldi; Salvatore Cucchiara
Journal:  Dig Dis Sci       Date:  2019-01-19       Impact factor: 3.199

Review 8.  Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis- Current Concepts and Perspectives for Steroid Use.

Authors:  Thomas Greuter; Jeffrey A Alexander; Alex Straumann; David A Katzka
Journal:  Clin Transl Gastroenterol       Date:  2018-12       Impact factor: 4.488

Review 9.  Pediatric eosinophilic esophagitis: a review for the clinician.

Authors:  Antonella Cianferoni; Elio Novembre; Simona Barni; Stefania Arasi; Carla Mastrorilli; Luca Pecoraro; Mattia Giovannini; Francesca Mori; Lucia Liotti; Francesca Saretta; Riccardo Castagnoli; Lucia Caminiti
Journal:  Ital J Pediatr       Date:  2021-11-22       Impact factor: 2.638

Review 10.  Evidence-based treatments for eosinophilic esophagitis: insights for the clinician.

Authors:  Sara Feo-Ortega; Alfredo J Lucendo
Journal:  Therap Adv Gastroenterol       Date:  2022-01-19       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.